Medicus Pharma(NASDAQ) MDCXW

Market CapN/A

Since IPO (2024)-50%

5 YearN/A

1 Year-68%

1 Month-4%

$0.30

+3.10%

+0.01Today

Medicus Pharma last closing stock price
Metric	Price	Date
Last close	USD 0.30	2026-10-13

Medicus Pharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-0.33%	USD 0.30	2026-10-06
1 month	-3.55%	USD 0.31	2026-09-10
3 month	-37.71%	USD 0.48	2026-07-15
Year to date	-62.63%	USD 0.80	2025-12-31
1 year	-67.59%	USD 0.92	2025-10-13
Since inception	-50.13%	USD 0.60	2024-11-14

Medicus Pharma Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$39.15M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$0.30

Volume

720

Open

$0.30

Price

$0.30

Volume

720

Open

$0.30

Previous Close

$0.30

Daily Range

$0.30 - $0.30

52-Week Range

$0.01 - $1.45

Estimated Earnings Date

Nov 20, 2026

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$0.30

Volume

720

Open

$0.30

Previous Close

$0.30

Daily Range

$0.30 - $0.30

52-Week Range

$0.01 - $1.45

Estimated Earnings Date

Nov 20, 2026

MDCXW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medicus Pharma

Medicus Pharma Ltd. is a biotechnology company focused on advancing clinical development programs for innovative therapeutic assets. The company is headquartered in Toronto, Canada, and is dedicated to developing products like SkinJectTM, aimed at treating basal cell carcinoma.

Products and Services

SkinJectTM for basal cell carcinoma treatment
Research and development of novel therapeutic assets
Clinical trial management and support services

Growth Outlook

Market potential for SkinJectTM in oncology is significant
Increased investment in R&D to enhance product pipeline
Strategic partnerships may accelerate market entry

Financial Highlights

Recent quarterly net income of -$8.39 million
Trailing twelve months (TTM) cash and cash equivalents of $10.7 million
Current ratio of 1.57 indicates strong liquidity position

Medicus Pharma Ltd. operates in the dynamic biotechnology sector, focusing on innovative solutions for unmet medical needs. The company's flagship product, SkinJectTM, targets basal cell carcinoma, a prevalent form of skin cancer. With a commitment to research and development, Medicus Pharma aims to expand its product offerings and enhance its market presence. The growth outlook for Medicus Pharma is promising, driven by the substantial market potential for its therapeutic assets. The company is actively investing in research and development, which may lead to the introduction of new products and services. Additionally, potential strategic partnerships could facilitate faster market entry and broaden the company's reach. Financially, Medicus Pharma has reported a recent quarterly net income loss, reflecting ongoing investments in R&D and operational expenses. However, the company maintains a solid liquidity position, as indicated by its current ratio. The cash reserves provide a buffer for continued operations and development efforts. Overall, Medicus Pharma Ltd. presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in innovative cancer treatments.

AI Generated • Oct 2, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

West Conshohocken, PA 19428, CA

MDCXW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

17867.26%

Return on Capital

-467.18%

Return on Assets

-204.84%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

720

Avg. Volume

960.918

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$37.78M

EBITDA

-$39.23M

Operating Cash Flow

-$22.90M

Capital Expenditure

-$2.00

Free Cash Flow

-$22.90M

Cash & ST Invst.

$10.70M

Total Debt

$15.25M

Medicus Pharma Performance Analysis

Medicus Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

Medicus Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-164.5%
Q4	2025-12-31	47.6%
Q1	2026-03-31	48.8%
Q2	2026-06-30	31.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$8.39M

-35.9%

EBITDA

-$8.29M

-34.3%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$10.70M

+10.6%

Total Debt

$15.25M

+207.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$12.69M

+8850.1%

Short Term Debt

$2.56M

-46.9%

Return on Assets

-2.05%

N/A

Return on Invested Capital

-3.29%

N/A

Free Cash Flow

-$4.96M

+9.3%

Operating Cash Flow

-$4.96M

+9.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

OTLKOutlook Therapeutics, Inc.

OTLKOutlook Therapeutics, Inc.$0.56-3.64%

NRXPNRx Pharmaceuticals, Inc.

NRXPNRx Pharmaceuticals, Inc.$2.70-5.26%

SPRBSpruce Biosciences, Inc.

SPRBSpruce Biosciences, Inc.$40.35-5.88%

ICCCImmuCell Corporation

ICCCImmuCell Corporation$10.79+12.40%

CUECue Biopharma, Inc.

CUECue Biopharma, Inc.$19.57-20.48%

IOBTIO Biotech, Inc.

IOBTIO Biotech, Inc.$0.01-27.59%

FBIOFortress Biotech, Inc.

FBIOFortress Biotech, Inc.$1.95-7.58%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

CIFRCipher Digital

CIFRCipher Digital$11.34-12.77%

BMBLBumble

BMBLBumble$5.95+56.58%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$37.42+0.62%

INTCIntel

INTCIntel$102.81+1.44%

NVDANvidia

NVDANvidia$228.52+0.97%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$127.57-0.65%

NOKNokia

NOKNokia$9.86-0.40%

Questions About MDCXW

What is the current price of Medicus Pharma?

Medicus Pharma is trading at $0.30 per share.

What is the 52-week range for Medicus Pharma?

Over the past 52 weeks, Medicus Pharma has traded between $0.01 and $1.45.

How much debt does Medicus Pharma have?

Medicus Pharma total debt is unavailable.

How much cash does Medicus Pharma have on hand?

Medicus Pharma does not have cash on hand data available.

What is Medicus Pharma’s dividend yield?

Medicus Pharma does not currently have a dividend yield.

Medicus Pharma(NASDAQ) MDCXW

Medicus Pharma Financials at a Glance

MDCXW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Medicus Pharma

MDCXW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Medicus Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MDCXW

What is the current price of Medicus Pharma?

What is the 52-week range for Medicus Pharma?

How much debt does Medicus Pharma have?

How much cash does Medicus Pharma have on hand?

What is Medicus Pharma’s dividend yield?

Premium Investing Services